
Pharmacally
Epilepsy
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Epilepsy
Mergers & AcquisitionsJazz Pharmaceuticals to Acquire Actio Biosciences to Expand Rare Epilepsy PortfolioJazz Pharmaceuticals will acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent payments, gaining ABS-1230, an investigational oral KCNT1 inhibitor being developed for…Fact-Checked
Clinical TrialsBiohaven’s Opakalim Nears Regulatory Filing as Biohaven Reports New Epilepsy DataBiohaven Ltd. unveiled new clinical data for opakalim (BHV‑7000), its selective Kv7.2/7.3 activator, during its annual R&D Day.Fact-Checked
Clinical TrialsXenon Presents Positive X-TOLE2 Results Supporting Azetukalner in EpilepsyPhase 3 X-TOLE2 data presented at the American Academy of Neurology Annual Meeting 2026 show azetukalner delivers significant seizure reduction and sustained long-term control in treatment-resistant focal epilepsy…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.